BETA: Please send your feedback!
Innoviva
INVA:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2021
—
About
Pharmaceuticals: Other
Founded 1996
Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| P. Roy Vagelos, MD | Founder | Male |
| Wesley D. Sterman, MD, MBA | Founder | Male |
| Jim B. Tananbaum, MD, MBA | Founder | Male |
| William H. Waltrip | Chairman | Male |
| George M. Whitesides, PhD | Founder | Male |
| Michael W. Aguiar, MBA | President, Chief Executive Officer & Director | Male |
| Eric d'Esparbes | Chief Financial Officer & Senior Vice President | Male |
| Mathai Mammen, MD, PhD | Founder | Male |
| John Hampton Griffin, PhD | Founder | Male |
| Theodore L. Witek, Jr., PhD | Chief Scientific Officer & Senior Vice President | Male |
Mindful Investing Summary
Innoviva - Competitors and Related Companies
How Innoviva stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.
Innoviva
INVA:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2021
—
Medicines
MDCO:NAS
Pharmaceuticals: Other
—
MID cap
(—)
—
since start of 2021
—
Mylan
MYL:NAS
Pharmaceuticals: Generic
—
LARGE cap
(—)
—
since start of 2021
—
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—
Novartis
NOVN-CH:SWX
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—
Pfizer
PFE:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2021
—